Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nivolumab treatment in a patient with BRAF mutant advanced melanoma and liver failure with encephalopathy.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners - 1 Apr 2024

Colak Rumeysa, Kapar Caner, Gulturk Ilkay, Yilmaz Mesut

Abstract excerpt

BACKGROUND: We report the case of a patient with melanoma and liver failure with encephalopathy, successfully treated with nivolumab without major side effects and encouraging prolonged disease control. CASE PRESENTATION: In June 2022, metastatic lesions appeared in the liver associated with melanoma progression under treatment. Liver biopsy was non-diagnostic. The patient developed fever, abdominal distension,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Liver Failure

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Neoplasms

Share to Melanoma

Share to Mutation

Share to Nivolumab

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 38111303
DOI: 10.1177/10781552231221230

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Nivolumab treatment in a patient with BRAF mutant advanced melanoma and liver failure with encephalopathy.PMID 38111303Read ↗

Successful Management of Suspected Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in BRAF-Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors: A Case Report.Semantic proximity Read ↗

Successful Management of BRAF V600E-Mutated Metastatic Colorectal Cancer With Liver Dysfunction Using Encorafenib-Based Therapy.Semantic proximity Read ↗

Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors.Semantic proximity Read ↗

Severe Ifosfamide-Associated Encephalopathy Requiring Mechanical Ventilation With Gradual Neurological Recovery During Methylene Blue Therapy: A Case ReportSemantic proximity Read ↗

Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS.Semantic proximity Read ↗

Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma - A case report and review of the literature.Semantic proximity Read ↗

Severe hepatotoxicity during treatment with capmatinib.Semantic proximity Read ↗

Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.